The increase in price target from $55 to $60 by Oppenheimer suggests a positive outlook on Revolution Medicines' future performance. The maintained Outperform rating indicates continued confidence from the analyst, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.